Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Jul 28;142(4):419-421.
doi: 10.1161/CIRCULATIONAHA.120.046320. Epub 2020 Jul 27.

Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial

Thorsten M Leucker  1 , Michael J Blaha  1 , Steven R Jones  1 , Michael A Vavuranakis  1 , Marlene S Williams  1 , Hong Lai  2 , Thomas H Schindler  3 , Jacqueline Latina  1 , Steven P Schulman  1 , Gary Gerstenblith  1
Affiliations
Randomized Controlled Trial

Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial

Thorsten M Leucker et al. Circulation. .
No abstract available

Keywords: acute coronary syndrome; cholesterol, LDL; evolocumab; secondary prevention.

PubMed Disclaimer

Figures

Figure.
Figure.. Atherogenic lipoprotein values and percent of patients achieving LDL-C, ApoB, and non-HDL-C AHA/ACC/ESC targets at hospital discharge and at 30-day follow-up in the evolocumab and placebo groups.
(A) Shown is a graph of the mean and standard deviation (SD) values for LDL-C at the studied time points in the two study groups. The number of participants assessed at the different time points are as follows: Baseline= 57 (evolocumab=30; placebo=27); Day 1=51 (evolocumab=26; placebo=25); Day 3=30 (evolocumab=16; placebo=14); Day 4–7=23 (evolocumab=15; placebo=8); 30-days=57 (evolocumab=30; placebo=27). Panels B and C: Displayed are the proportions of participants whose LDL-C, non-HDL-C, and ApoB levels were at or below 2018 AHA/ACC and 2019 ESC secondary prevention targets at hospital discharge (B) and at 30-day follow-up (C) in the evolocumab and placebo groups. The mean discharge day was 4±2 days, similar to that of the national average. Discharge values were obtained within 24-hours of discharge (evolocumab n=26; placebo n=21). We excluded the values of 10 participants; two who were discharged <24 hrs after randomization, six who were discharged >7 days after study drug administration and two who declined follow up blood drawing during the hospitalization but presented for the 30-day follow-up lipid measurements. For panel A the p-values were obtained using two-sample t-tests and for panels B and C, p-values were obtained using the Fisher’s exact test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E and PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411–1416. - PubMed
    1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. - PMC - PubMed
    1. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097–2107. - PubMed
    1. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T and Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: A randomized controlled trial. JAMA. 2001;285:1711–1718. - PubMed
    1. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Haner J, Gencer B, Crljenica C, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74:2452–2462. - PubMed

Publication types

MeSH terms